The stock of AN2 Therapeutics Inc (ANTX) has seen a -2.78% decrease in the past week, with a -4.55% drop in the past month, and a -25.00% decrease in the past quarter. The volatility ratio for the week is 3.90%, and the volatility levels for the past 30 days are at 4.64% for ANTX. The simple moving average for the past 20 days is -4.20% for ANTX’s stock, with a -13.16% simple moving average for the past 200 days.
Is It Worth Investing in AN2 Therapeutics Inc (NASDAQ: ANTX) Right Now?
ANTX has 36-month beta value of -0.08. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy”, 1 as “overweight”, 1 as “hold”, and 1 as “sell”.
The public float for ANTX is 17.04M, and currently, short sellers hold a 0.31% ratio of that float. The average trading volume of ANTX on July 04, 2025 was 220.48K shares.
ANTX stock’s latest price update
AN2 Therapeutics Inc (NASDAQ: ANTX) has seen a decline in its stock price by -2.78% in relation to its previous close of $1.08. However, the company has experienced a -2.78% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-06-30 that MENLO PARK, Calif.–(BUSINESS WIRE)–AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the completion of a 200-patient observational study in acute melioidosis, a highly lethal bacterial infection and recognized biothreat. The study, conducted under real-world conditions in acute hospital settings, evaluated patients receiving the current standard of care (SoC).
Analysts’ Opinion of ANTX
Many brokerage firms have already submitted their reports for ANTX stocks, with Leerink Partners repeating the rating for ANTX by listing it as a “Market Perform”. The predicted price for ANTX in the upcoming period, according to Leerink Partners is $1 based on the research report published on August 09, 2024 of the previous year 2024.
JMP Securities gave a rating of “Mkt Outperform” to ANTX, setting the target price at $6 in the report published on April 02nd of the previous year.
ANTX Trading at -8.95% from the 50-Day Moving Average
After a stumble in the market that brought ANTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.80% of loss for the given period.
Volatility was left at 4.64%, however, over the last 30 days, the volatility rate increased by 3.90%, as shares sank -3.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.15% lower at present.
During the last 5 trading sessions, ANTX fell by -2.78%, which changed the moving average for the period of 200-days by +0.96% in comparison to the 20-day moving average, which settled at $1.0960. In addition, AN2 Therapeutics Inc saw -50.70% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANTX starting from Leonard Braden Michael, who sold 200,000 shares at the price of $1.09 back on May 28 ’25. After this action, Leonard Braden Michael now owns 3,017,432 shares of AN2 Therapeutics Inc, valued at $218,000 using the latest closing price.
Easom Eric, the Chief Executive Officer of AN2 Therapeutics Inc, purchase 10,000 shares at $1.07 during a trade that took place back on Jun 02 ’25, which means that Easom Eric is holding 256,380 shares at $10,665 based on the most recent closing price.
Stock Fundamentals for ANTX
The total capital return value is set at -0.68%. Equity return is now at value -49.32%, with -44.77% for asset returns.
Currently, EBITDA for the company is -51.32 million with net debt to EBITDA at 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.68.
Conclusion
To put it simply, AN2 Therapeutics Inc (ANTX) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
